Adrien Costantini, Theodoros Katsikas and Clementine Bostantzoglou* Pages 5 - 10 ( 6 )
Over the past decade, major breakthroughs in the understanding of lung cancer histology and mutational pathways have radically changed diagnosis and management. More specifically, in non-small cell lung cancer (NSCLC), tumour characterisation has shifted from differentiating based solely on histology to characterisation that includes genetic profiling and mutational status of Epidermal Growth Factor (EGFR), Anaplastic Lymphoma Kinase (ALK), c-ros oncogene 1 (ROS1) and BRAF. These genetic alterations can be targeted by specific drugs that result in improved progression-free survival, as well as higher response rates and are currently standard of care for NSCLC patients harbouring these mutations. In this a narrative, non-systematic review we aim to handpick through the extensive literature and critically present the ground-breaking studies that lead to the institution of tailored treatment options as the standard of care for the main targetable genetic alterations.
Anaplastic lymphoma kinase, epidermal growth factor, non-small-cell lung cancer, targeted therapies, tyrosine kinase inhibitors, mutation.
Hopital Saint-Louis Service de Pneumologie, Paris, General and Oncology Hospital of Kifissia “Agioi Anargyroi”, Second Department of Internal Medicine, Athens, Intensive Care Unit, Korgialeneion-Benakeion General Hospital, Athens